Sponsors and Collaborators
Fernando C Fervenza, M.D., Ph.D.
Lori A Riess
- Age >18 years
- Proteinuria > 5g/24h despite ACEi and/or ARB treatment for > 3 months
- Estimated or quantified GFR > 40 ml/min/1.73m2 while taking ACEi/ARB therapy
- Resistant to cyclosporine (CSA) are excluded but patients who initially responded to CSA but relapsed off CSA are eligible for the study
Fernando C. Fervenza, M.D., Ph.D., Mayo Clinic
Next post in Lupus Nephritis Clinical Trials
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
Want to read more?
Please login or register first to view this content.